Caplin Point Q1 FY27: Strong Growth, Large Liquidity, and a Capex-Led Scale-Up

Caplin Point Laboratories opened FY27 with another quarter of high growth and high profitability, while continuing to invest heavily in capacity and vertical integration. For Q1 FY27, consolidated total revenue was INR 643.9 crore, up 20.7% year on year. Revenue from operations rose 19.6% to INR 610.4 crore. Profit after tax came in at INR 179.1 crore, up 18.8%.

Margins stayed structurally strong. Gross margin was 59.8% in Q1 FY27 versus 61.7% in Q1 FY26, while EBITDA margin improved to 38.4% from 37.7%. Profit before tax rose 22.1% to INR 225.2 crore, and PAT margin stood at 27.8%.

The quarter also carried a clear message on balance sheet strength. The company disclosed free cash reserves of INR 1,502 crore and total liquid assets of INR 2,875 crore as of 30 June 2026. Management reiterated that the ongoing investment cycle is funded through internal accruals, with an intent to remain net cash positive.

What drove the quarter: growth across Rest of World and the US

Caplin’s consolidated segment reporting is organized by geography, with two reportable segments: Rest of the World and USA. For Q1 FY27, segment revenue showed Rest of the World at INR 476.1 crore and USA at INR 134.3 crore, with other income classified as unallocated.

The press release also described a Q1 FY27 geographic revenue composition in the range of 78% for emerging markets and 22% for the US. Management commentary highlighted steady momentum in Latin America and accelerating contribution from the US platform.

On the emerging markets side, the company pointed to emergency tenders in Central America worth USD 7 million to be supplied over the next two quarters, and Chile tenders worth USD 12 million to be supplied over the next 18 months. Mexico continues to be positioned as a key expansion market, with four additional product approvals and a pipeline of 120+ products planned to be filed in the next 18 months.

On the US and regulated markets side, Caplin Steriles Limited continued to scale. The company stated it has 60 ANDAs approved and 5 under review, with 38 products launched in the US so far and a plan to launch 12 more products in FY27. It also highlighted a broader regulated-market filing strategy beyond the US, including products filed in Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi Arabia and the UAE.

Financial snapshot

Working capital and cash flow: why CFO softened

One soft spot in the quarter was operating cash flow. The company reported cash flow from operations of INR 95 crore in Q1 FY27 versus INR 118 crore in Q1 FY26.

Management addressed this directly on the concall. The CFO attributed the moderation primarily to a conscious increase in warehouse stock and raw material packaging inventory, aimed at shielding against supply chain disruption amid geopolitical risks and potential raw material price increases. Inventories were disclosed at INR 505 crore as of 30 June 2026, and the press release gave a detailed inventory location split: 47% at warehouses close to customers, 23% in transit, and 30% in India. Receivables were disclosed at 128 days.

The CFO also said receivables increased due to government supplies in the quarter, and indicated these are expected to be received by Q3 FY27. He added that the increases are not likely to repeat in the same quantum from Q2 onward, and therefore cash flow from operations is expected to improve.

The strategy: capacity, compliance, and backward integration

Caplin’s current narrative is less about a single-quarter beat and more about building a larger platform across geographies and dosage forms. The press release and investor presentation lay out a capex program of approximately INR 1000+ crore, with around 50% nearing completion and the balance planned over the next 2 to 3 years. The company stated this capex is to augment capacity, widen the product range, and achieve backward integration for a majority of products.

A key capacity project for the regulated markets is the COL-II facility, which management said is targeted to be completed by March 2027. It is planned to house five injectable, ophthalmic and BFS lines, with provision to add three more lines.

The company also described a pipeline of complexity upgrades. CSL plans to file its first pre-filled syringe product within FY27, with a larger set of 14+ PFS products planned for FY28.

On backward integration, Caplin highlighted progress at its API programs. Its general API unit in Vizag completed scale-up for six APIs and aims to file the first few DMFs from this site in FY26-FY27. The oncology API facility at Therovoy SIPCOT is expected to be completed by Q3 or Q4 FY27, with first DMFs planned in the following year.

Beyond steriles and APIs, Caplin is expanding oral solids and dermatology capacity in Puducherry. The company said the facility is intended to expand capacities by over two times and also enable entry into regulated markets for those dosages, with a Q1 FY28 timeline.

A supporting pillar is Amaris Clinical, which is being expanded up to 120 beds by end of FY27. On the concall, management said Amaris will largely be used for internal bio studies for the next couple of years and cited an indicative cost advantage of roughly 50% versus external BE centers.

Segment view: where revenue is coming from

The company also disclosed that its revenue composition includes product supply and milestone plus profit share, with a Q1 FY27 split described as approximately 85% and 15% respectively. This provides context on how the group’s earnings can be supported by a mix of supply-led sales and partnership economics, although the documents do not provide absolute rupee numbers for these components.

Corporate actions and governance updates

Alongside results, the board recommended a final dividend of INR 4 per equity share (200%) for FY26, subject to shareholder approval. The company also approved the re-appointment of Dr. Sridhar Ganesan as Managing Director for two years from 25 August 2026 to 24 August 2028, and appointed Mr. D. Muralidharan as Whole-Time Director for two years from 12 August 2026 to 11 August 2028, while continuing as CFO.

Takeaways

Caplin Point’s Q1 FY27 performance was built on continued growth in its core emerging markets franchise and a steadily scaling US platform. The financial profile remains distinctive: strong margins, negligible finance costs, and large disclosed liquidity. At the same time, the company is deliberately accepting a working-capital build, positioning it as a risk-management move to protect continuity of supply.

The bigger story is the build-out of capacity and capabilities across steriles, ophthalmics, BFS, oral solids, and APIs. With multiple facilities scheduled through FY27 and FY28, execution and regulatory timelines will be the key variables to track. Management’s commentary makes it clear the company intends to fund this scale-up through internal accruals while remaining net cash positive, which, if delivered, would keep Caplin’s balance sheet advantage intact even through a heavy investment phase.